Shi Y, Chen G, Wang X, Liu Y, et al. Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study. J Thorac Oncol 2022 Aug 3. pii: S1556-0864(22)01496.
PMID: 35932953